Parkinson’s Disease

This is our library on scientific research related to CBD, the Endocannabinoid System, other cannabinoids and Parkinson’s Disease. Below you will find a list of conditions for which there are one or more scientific studies of CBD. The source of these scientific studies relates primarily to PubMed, an online service of the U.S. National Library of Medicine.

Important: The studies that are listed by PubMed are for the most part preclinical research. These relate in most cases to animal experiments with isolated CBD (pure CBD) and not fully extracted CBD extract. Although mammals have cell receptors that respond to cannabinoid compounds, the data collected from animal studies are not always 1: 1 applicable to humans. Always check with your physician before starting a new dietary supplement program. Learn more at: The Basics of CBD Oils and Cannabis as a Therapeutic Agent

Cannabidiol for the treatment of psychosis in Parkinson’s disease
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease
CB2 Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson’s Disease
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties
Neurological aspects of medical use of CBD
Prospects for cannabinoid therapies in basal ganglia disorders  
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease
Therapeutic potential of cannabinoids in CNS disease

Send this to a friend